Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Virtual Congress 2020

19 Sep - 18 Oct 2020

Switzerland

ESMO 2020 Virtual Congress 1000x1000

Presentations (slides) and webcasts are available to ESMO members and attendees according to the presenters' agreement to release them. Abstracts are open access.

Find resources from the Science Weekend

Saturday 19 - Sunday 20 - Monday 21

and the Education Weekend: Educational sessions

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

The latest advances in Oncology​

Special sessions and Tracks

More from #ESMO20

Video Highlights | Expert video reports

Hide
Filter by:

There are 2949 resources available

Conclusion: Is RET targeting ready for an agnostic use?

Presenter: Alexander Drilon

Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment

Resources:

Slides

Webcast

Live Q&A

Presenter: Alexander Drilon

Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment

Resources:

Webcast

Is Osimertinib the best single agent if 1st line?

Presenter: Myung-Ju Ahn

Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?

Resources:

Slides

Webcast

Should chemotherapy be combined upfront with EGFR TKI?

Presenter: Ross Soo

Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?

Resources:

Slides

Webcast

Is a combination of anti-angiogenic with EFGR TKI a new standard

Presenter: Martin Reck

Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?

Resources:

Slides

Webcast

Do immune check point work in EGFR TKI?

Presenter: Edward Garon

Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?

Resources:

Slides

Webcast

In a multiline setting, what is the best sequencing?

Presenter: Enriqueta Felip

Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?

Resources:

Slides

Webcast

Conclusions

Presenter: Myung-Ju Ahn

Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.